Dario Alessi

USPTO Granted Patents = 10 (Patent Applications = 6)

EPO Patents = 2 (Patent Applications = 7)

Average Co-Inventor Count = 1.7

ph-index = 1

Forward Citations = 9(Granted Patents)

Company Filing History:

8 out of 259

Medical Research Council

Years Active: 2004-2013

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8367349 - Methods for identifying modulators of LRRK2 (2013-02-05),

2. 8206942 - Methods of identifying LRRK2 inhibitors (2012-06-26),

3. 7947468 - Methods (2011-05-24),

4. 7897371 - Activation of mutated RAC-PK (2011-03-01),

5. 7842488 - Polynucleotides encoding a human 3-phosphoinositide- dependent protein kinase (2010-11-30),

6. 7792665 - Method for designing a compound based on the three dimensional structure of phosphoinositide dependent protein kinase 1 (PDK1) (2010-09-07),

7. 7344870 - 3-phosphoinositide-dependent protein kinase (2008-03-18),

8. 7205390 - Enzyme (2007-04-17),

9. 7122360 - Polypeptides, polynucleotides and uses thereof (2006-10-17),

10. 6734001 - 3-phosphoinositide-dependent protein kinase (2004-05-11),

Title: Dario Alessi: Innovator in Parkinson's Disease Research

Introduction

Dario Alessi is a distinguished inventor based in Dundee, GB, known for his significant contributions in the field of molecular biology and neurobiology. With a total of 10 patents to his name, Alessi's research primarily focuses on understanding and modulating LRRK2, a protein linked to Parkinson's Disease.

Latest Patents

Alessi's latest patents showcase innovative methods for identifying modulators of LRRK2. One of his noteworthy patents details a method for assessing the impact of test compounds on the phosphorylation state of LRRK2 in a cell-based system. This method involves steps such as evaluating the effect of these compounds on LRRK2’s phosphorylation state at specific serine residues and determining the protein's binding affinity to 14-3-3 polypeptides. These methods hold the potential to assess LRRK2 inhibitors' effects, providing valuable insights into therapies for Parkinson's Disease.

Another significant patent outlines a method for identifying compounds that can modulate LRRK2 protein kinase activity. This process includes determining whether a test compound inhibits the protein kinase activity of LRRK2 on a substrate polypeptide, which may serve as a crucial step in developing effective treatments for Parkinsonism.

Career Highlights

Throughout his career, Dario Alessi has collaborated with prominent research institutions such as the Medical Research Council and the University of Dundee. His dedication to advancing scientific knowledge has led to breakthroughs that could significantly impact the understanding and treatment of neurodegenerative diseases.

Collaborations

Alessi has worked alongside esteemed colleagues such as R Jeremy Nichols and Philip Cohen. These collaborations foster an environment of creativity and innovation that drives forward the field of Parkinson's research.

Conclusion

Dario Alessi exemplifies the spirit of innovation in scientific research. His patents not only contribute to the understanding of LRRK2 but also pave the way for potential therapies for Parkinson's Disease. With his continuous efforts in invention and research, he remains a pivotal figure in the scientific community.

This text is generated by artificial intelligence and may not be accurate.